Abiopharma

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

Oculis tilkynnir um að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hafi veitt Privosegtor stöðu byltingarkennds meðferðarlyfs til meðhöndlunar á sjóntaugabólgu

Appendix 3Y for Gregory George

Notification of cessation of securities - MSB

Saphnelo self-administration TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in SLE disease activity

Hyphens Notification - Media Release: Hyphens Pharma out-licences Cerapro® MED Skin Barrier Cream for six European countries

argenx to Present at 44th Annual J.P. Morgan Healthcare Conference

PMGC Holdings Inc. Announces Reverse Stock Split Effective January 6, 2026

O'Brien Patrick 🔴 sold 52.3K shares of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) at $68.00 ($3.1M) Transaction Date: Dec 31, 2025 | Filing ID: 000001

Hamilton James C 🔴 sold 40.2K shares of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) at $68.00 ($2.5M) Transaction Date: Jan 05, 2026 | Filing ID: 000002

Director Anzalone Christopher Richard 🔴 sold 13.2K shares of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) at $66.39 Transaction Date: Jan 02, 2026 | Filing ID: 000001

Director Nijhawan Pardeep 🟢 acquired 10.4K shares of Edesa Biotech, Inc. (EDSA) Transaction Date: Jan 05, 2026 | Filing ID: 000069

📋 Henry E. Pelish (Officer) plans to sell 2K shares of NUVALENT, INC. (at $97.32 each, total $243K) Filed: Jan 05, 2026 | ID: 003156

📋 Darlene Noci (Officer) plans to sell 4K shares of NUVALENT, INC. (at $97.32 each, total $412K) Filed: Jan 05, 2026 | ID: 003155

📋 Deborah Ann Miller (Officer) plans to sell 4K shares of NUVALENT, INC. (at $97.32 each, total $425K) Filed: Jan 05, 2026 | ID: 003154